Boehringer Ingelheim Venture Fund
Corporate venture fund established in 2010 that invests in first-in-class, disease-modifying therapeutics across modalities. The fund is globally active in the EU, US and China and focuses on early-stage company formation and Seed/Series A investments aligned with Boehringer Ingelheim's strategic interests.
Industries
Nr. of Employees
small (1-50)
Boehringer Ingelheim Venture Fund
Binger Strasse 173, 55216 Ingelheim am Rhein, Germany
Portfolio
Develops bespoke AI models and a foundation model for pathology in collaboration with Mayo Clinic; board representative Oliver Reuß.
#Digital Health (computational pathology for drug R&D and diagnostics)
Developing an ML-powered discovery platform combining image-based AI and cheminformatics for novel small molecule identification; board representative Fei Shen.
#Drug discovery / AI (small molecule therapeutics)
Preclinical company developing innovative biologics for diabetic patients; board representative Manuel Baader.
#Diabetes / Biologics
Develops cough-monitoring solutions for diagnosis and management of cough-incident conditions; board representative Oliver Reuß.
#Digital Health (cough monitoring and diagnostics)
Swiss biotech using a cell-penetrating peptide platform to develop protein-based cancer vaccines; acquired by Boehringer Ingelheim in 2019.
#Oncology (therapeutic vaccines)
Research-stage company developing antibody-based drugs; acquired by Boehringer Ingelheim in 2021.
#Oncology (antibody-based therapeutics)
Develops bespoke AI models and a foundation model for pathology in collaboration with Mayo Clinic; board representative Oliver Reuß.
#Digital Health (computational pathology for drug R&D and diagnostics)
Developing an ML-powered discovery platform combining image-based AI and cheminformatics for novel small molecule identification; board representative Fei Shen.
#Drug discovery / AI (small molecule therapeutics)
Preclinical company developing innovative biologics for diabetic patients; board representative Manuel Baader.
#Diabetes / Biologics
Develops cough-monitoring solutions for diagnosis and management of cough-incident conditions; board representative Oliver Reuß.
#Digital Health (cough monitoring and diagnostics)
Swiss biotech using a cell-penetrating peptide platform to develop protein-based cancer vaccines; acquired by Boehringer Ingelheim in 2019.
#Oncology (therapeutic vaccines)
Research-stage company developing antibody-based drugs; acquired by Boehringer Ingelheim in 2021.
#Oncology (antibody-based therapeutics)